Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia
- 25 September 2007
- journal article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 26 (12), 907-914
- https://doi.org/10.1007/s10096-007-0383-4
Abstract
Candidemia is an increasing complication of the care of complex patients. Adherence to Infectious Diseases Society of America (IDSA) guidelines for the treatment of candidemia was investigated to assess the impact of compliance on outcomes of therapy. Data on the epidemiology, diagnosis, and treatment of patients with invasive fungal infections (IFIs) was extracted from the PATH Alliance registry, a prospective, multicenter, observational database of invasive fungal infections. Patients with proven candidemia were evaluated for adherence to the IDSA guidelines in terms of choice, dosage, and duration of antifungal therapy. Removal of central venous catheters and time to treatment initiation were assessed. Four-week survival data were compared. Of the 418 patients with candidemia who were included in the study, 361 patients with the necessary data sets were identified, of whom 262 (72.6%) were treated within the IDSA guidelines for the treatment of candidemia (IDSA group); the remaining 99 (27.4%) patients received treatment different from the guidelines (non-IDSA group). Kaplan-Meier (KM) survival analysis for patients in the IDSA and non-IDSA group showed mortality rates of 21.9 and 13.6%, respectively; the difference between the two groups was not statistically significant (P = 0.093). Following the exclusion of patients requiring mechanical ventilation or acute cardiac support, the modified survival KM curves were similar between the two groups. Significantly more patients in the IDSA group required mechanical ventilation and tunneled central catheters, had a concomitant IFI, and received caspofungin. The duration of treatment and inappropriate dosing did not appear to have had a significant impact on survival. Most of the deviations from IDSA guidelines were due to the inappropriate duration and dosing of therapy. No significant difference in mortality was noted between the IDSA and non-IDSA groups. The basis of these differences merit further study.Keywords
This publication has 13 references indexed in Scilit:
- The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity AnalysisClinical Infectious Diseases, 2005
- Initial management of candidemia at an academic medical center: Evaluation of the IDSA guidelinesDiagnostic Microbiology and Infectious Disease, 2005
- Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance StudyClinical Infectious Diseases, 2004
- Guidelines for Treatment of CandidiasisClinical Infectious Diseases, 2004
- Attributable Mortality of Nosocomial Candidemia, RevisitedClinical Infectious Diseases, 2003
- Comparison of Caspofungin and Amphotericin B for Invasive CandidiasisThe New England Journal of Medicine, 2002
- Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International ConsensusClinical Infectious Diseases, 2002
- Practice Guidelines for the Treatment of CandidiasisClinical Infectious Diseases, 2000
- Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year AnalysisClinical Infectious Diseases, 1999
- Hospital-acquired candidemia. The attributable mortality and excess length of stayArchives of Internal Medicine, 1988